Post-Bariatric Hypoglycemia Market to Register Stunning Growth at a 16.4% CAGR Through 2036 Owing to the Emergence of Novel Drug Classes Such as GLP-1 Receptor Antagonists, SGLT1 Inhibitors, CRH Inhibitors, and SSTR5 Agonists | DelveInsight

The post-bariatric hypoglycemia market landscape is undergoing a significant transformation, moving beyond traditional dietary modifications and off-label therapies such as acarbose, diazoxide, calcium channel blockers, and somatostatin analogues toward targeted, mechanism-driven treatments. Emerging therapies, including Avexitide (Amylyx Pharmaceuticals), Mizagliflozin (Vogenx), Pasireotide (SIGNIFOR) (Recordati Group), Imapextide (MBX 1416) (MBX Biosciences), and others, are attracting considerable interest for their potential to reduce hypoglycemic episodes, enhance glycemic control, and address the underlying pathophysiological mechanisms of PBH.

LAS VEGAS, July 7, 2026 /PRNewswire/ — Recently published Post-Bariatric Hypoglycemia Market Insights report includes a comprehensive understanding of current treatment practices, post-bariatric hypoglycemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 

Post-Bariatric Hypoglycemia Market Summary

• The market size for post-bariatric hypoglycemia was found to be USD 470 million in the 7MM in 2025.
• The United States accounted for the largest post-bariatric hypoglycemia treatment market size, approximately 73% of the total market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• The total prevalent cases of PBH in the 7MM were approximately 744,700 in 2025.
• Leading post-bariatric hypoglycemia companies, such as Amylyx Pharmaceuticals, Vogenx, Recordati Group, MBX Biosciences, Confo Therapeutics, Gubra, Hanmi, and others, are developing new post-bariatric hypoglycemia treatment drugs that can be available in the post-bariatric hypoglycemia market in the coming years. 
• The promising post-bariatric hypoglycemia therapies in clinical trials include Avexitide, Mizagliflozin, Pasireotide (SIGNIFOR), Imapextide (MBX 1416), CFTX-2034, AMX0318, Efpegerglucagon, and others.

Discover what is the future of the post-bariatric hypoglycemia treatment market @ https://www.delveinsight.com/report-store/post-bariatric-hypoglycemia-market

Key Factors Driving the Growth of the Post-Bariatric Hypoglycemia Market 

• Rising PBH Prevalence: The increasing prevalence of PBH, particularly among females, is a primary driver of PBH market expansion. In the US, in 2025, there were ~428,500 prevalent cases of PBH.
• Rising Opportunities in Targeted Therapies for PBH: Increasing insights into the underlying pathophysiology of PBH are driving the development of targeted therapies designed to improve postprandial glucose regulation and mitigate hyperinsulinemic hypoglycemia, addressing a significant unmet clinical need.
• Rising Clinical Trial Activities: The PBH therapeutic pipeline remains limited, with no approved pharmacological treatments currently available. However, the development landscape is gaining momentum with emerging candidates such as Avexitide (Amylyx Pharmaceuticals), Mizagliflozin (Vogenx), Pasireotide (SIGNIFOR) (Recordati Group), Imapextide (MBX 1416) (MBX Biosciences), CFTX-2034 (Confo Therapeutics), AMX0318 (Amylyx Pharmaceuticals and Gubra), Efpegerglucagon (Hanmi), and others, highlighting a growing emphasis on targeted therapies for the management of postprandial hyperinsulinemic hypoglycemia associated with PBH.
• Emergence of Novel Drug Class: Emerging therapeutic classes for PBH include GLP-1 receptor antagonists, sodium-glucose transporter 1 (SGLT1) inhibitors, corticotropin-releasing hormone inhibitors, and SSTR5 agonists, reflecting an increasing emphasis on mechanism-based treatment strategies.

Sharad Chandra Vinayak, Assistant Project Manager of Forecasting at DelveInsight, said that due to the limited pipeline, mizagliflozin and avexitide might face less competition among branded drugs due to the novel MoA and can flourish in the market.

Post-Bariatric Hypoglycemia Market Analysis

• Post-bariatric hypoglycemia is currently managed primarily with off-label therapies, as there are no FDA-approved treatments specifically indicated for the condition. 
• Acarbose is widely used as the first-line pharmacological option; however, its clinical utility is frequently limited by gastrointestinal adverse effects. 
• Other off-label agents, including diazoxide and octreotide, have demonstrated variable efficacy, but their use is often constrained by tolerability issues, side effects, and poor patient adherence. 
• As the clinical burden of PBH continues to grow, significant unmet needs remain, driving the development of targeted, mechanism-based therapies. 
• Among these, GLP-1 receptor antagonists have emerged as one of the most promising therapeutic approaches by mitigating the exaggerated GLP-1-mediated insulin response that underlies PBH. 
• Leading candidates in this class include Avexitide and Imapextide (MBX 1416). The broader development landscape is also expanding to encompass novel therapeutic modalities such as sodium-glucose transporter 1 (SGLT1) inhibitors, corticotropin-releasing hormone (CRH) inhibitors, and SSTR5 agonists, reflecting an increasing emphasis on disease-specific treatment strategies. 
• Avexitide, being developed by Amylyx Pharmaceuticals, is currently the most advanced candidate in Phase III clinical development and is well-positioned to potentially gain a first-mover advantage in a market without approved therapies. 
• Overall, the PBH pipeline includes investigational candidates from companies such as Amylyx Pharmaceuticals, Recordati Group, Vogenx, MBX Biosciences, and Hanmi, spanning multiple stages of clinical development. 
• Despite encouraging progress, the pipeline remains relatively early-stage, with most programs evaluated in small patient cohorts, underscoring the need for larger, long-term clinical studies to establish sustained efficacy, safety, reproducibility of outcomes, and effectiveness across diverse patient populations.

Post-Bariatric Hypoglycemia Competitive Landscape

Some of the PBH drugs under development include Avexitide (Amylyx Pharmaceuticals), Mizagliflozin (Vogenx), Pasireotide (SIGNIFOR) (Recordati Group), Imapextide (MBX 1416) (MBX Biosciences), CFTX-2034 (Confo Therapeutics), AMX0318 (Amylyx Pharmaceuticals and Gubra), Efpegerglucagon (Hanmi), and others.

Amylyx Pharmaceuticals’ Avexitide (exendin 9-39) is a 31-amino acid peptide that selectively antagonizes glucagon-like peptide-1 (GLP-1) receptors, thereby reducing inappropriate pancreatic insulin secretion and mitigating both fasting and postprandial hypoglycemia in patients with post-bariatric hypoglycemia (PBH). The therapy has been granted both Breakthrough Therapy Designation and Orphan Drug Designation by the U.S. FDA for the treatment of hyperinsulinemic hypoglycemia, a hallmark feature of PBH.

Vogenx’s Mizagliflozin is an orally administered, minimally absorbed sodium-glucose cotransporter 1 (SGLT1) inhibitor designed to address the underlying pathophysiology of PBH. Patients with PBH exhibit elevated intestinal SGLT1 activity, leading to rapid glucose absorption, exaggerated postprandial glycemic excursions, and excessive insulin secretion. By inhibiting SGLT1-mediated glucose uptake in the intestine, mizagliflozin delays and reduces postprandial glucose absorption, thereby moderating insulin release and lowering the risk of hypoglycemic episodes. The therapy is currently being evaluated in a Phase IIb clinical trial.

MBX Biosciences’ Imapextide (MBX 1416) is a long-acting GLP-1 receptor antagonist peptide developed to reduce excessive insulin secretion and prevent recurrent hypoglycemic events in patients with PBH. Built on MBX Biosciences’ Precision Endocrine Peptide platform, the therapy is designed to provide sustained GLP-1 receptor blockade with less frequent dosing, potentially improving patient convenience and treatment adherence. Imapextide has also received U.S. FDA Orphan Drug Designation for the treatment of post-bariatric hypoglycemia.

The anticipated launch of these emerging therapies are poised to transform the post-bariatric hypoglycemia market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the post-bariatric hypoglycemia market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about which pipeline drugs could transform post-bariatric hypoglycemia treatment @ Post-Bariatric Hypoglycemia Drugs 

Recent Developments in the Post-Bariatric Hypoglycemia Market

• In May 2026, Amylyx Pharmaceuticals announced the launch of a US Expanded Access Program (EAP) for up to 250 adults with PBH to provide treatment access to avexitide. 
• In March 2026, MBX Biosciences announced that they anticipate the top-line results of the imapextide Phase II trial (STEADI) in the second quarter of 2026.
• In March 2026, Amylyx Pharmaceuticals announced that the last participant had been randomized and dosed in the pivotal Phase III (LUCIDITY) clinical trial of avexitide in PBH.
• In March 2026, Amylyx Pharmaceuticals announced that the topline results from the Phase III (LUCIDITY) evaluating avexitide in PBH are anticipated in Q3 2026, and if approved, the commercial launch is anticipated in 2027.
• In February 2026, Recordati Group announced that they anticipate the top-line results of the pasireotide Phase II trial in the second quarter of 2026.
• In February 2026, Recordati Group announced that they had completed the enrollment of the pasireotide Phase II trial for the treatment of PBH in August.

What is Post-Bariatric Hypoglycemia

Post-Bariatric Hypoglycemia (PBH) is a metabolic complication that occurs in some individuals following bariatric procedures, particularly Roux-en-Y gastric bypass and, less commonly, sleeve gastrectomy. It is characterized by recurrent episodes of low blood glucose, typically occurring 1–3 hours after meals, due to an exaggerated insulin response triggered by the rapid delivery of nutrients into the small intestine. Common symptoms include sweating, tremors, palpitations, dizziness, confusion, blurred vision, and, in severe cases, seizures or loss of consciousness, which can significantly impair quality of life. Although the exact pathophysiology is multifactorial, altered gut hormone secretion, especially increased glucagon-like peptide-1 (GLP-1) activity, along with enhanced insulin sensitivity and impaired counter-regulatory mechanisms, are considered key contributors. The condition is initially managed through dietary modifications, such as consuming frequent low-glycemic meals rich in protein and fiber, while pharmacological therapies and, in rare refractory cases, surgical interventions may be required for persistent symptoms.

Post-Bariatric Hypoglycemia Epidemiology Segmentation

The post-bariatric hypoglycemia epidemiology section provides insights into the historical and current post-bariatric hypoglycemia patient pool and forecasted trends for the leading markets. The observed female predominance and earlier onset of PBH highlight the importance of early postoperative monitoring, timely diagnosis, individualized nutritional management, and targeted therapeutic interventions to reduce hypoglycemic complications and improve long-term patient outcomes.

The post-bariatric hypoglycemia treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• Total Prevalence Cases of Post-Bariatric Hypoglycemia
• Total Prevalent Cases of PBH by Type of Bariatric Surgery
• Gender-specific Cases of Post-Bariatric Hypoglycemia
• Type-specific Cases of Post-Bariatric Hypoglycemia
• Total Treated Cases of Post-Bariatric Hypoglycemia

Scope of the Post-Bariatric Hypoglycemia Market Report

• Post-Bariatric Hypoglycemia Patient Population Forecast
• Post-Bariatric Hypoglycemia Therapeutics Market Size
• Post-Bariatric Hypoglycemia Pipeline Analysis
• Post-Bariatric Hypoglycemia Market Size and Trends
• Post-Bariatric Hypoglycemia Market Opportunity
• Post-Bariatric Hypoglycemia Market Unmet Needs
• KOL’s Views on Post-Bariatric Hypoglycemia
• Post-Bariatric Hypoglycemia Market Access and Reimbursement

Download the report to understand the top emerging therapies in post-bariatric hypoglycemia @ Post-Bariatric Hypoglycemia Market Analysis

Table of Contents

Related Reports

GLP Agonists Market

GLP Agonists Market Size, Target Population, Competitive Landscape & Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key GLP agonists companies, including Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk, Amgen, Viking Therapeutics, Regor Therapeutics, Carmot Therapeutics, Roche, GlaxoSmithKline, Sanofi, and others.

GLP Agonists Clinical Trial Analysis

GLP Agonists Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key GLP agonists companies, including Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk, Amgen, Viking Therapeutics, Regor Therapeutics, Carmot Therapeutics, Roche, GlaxoSmithKline, Sanofi, and others.

SGLT Inhibitors Market

SGLT Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SGLT inhibitors companies, including Youngene Therapeutics, Jeil Pharmaceuticals, TheracosBio, Eli Lilly, and others.

Non-alcoholic Fatty Liver Disease Market

Non-alcoholic Fatty Liver Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NAFLD companies, including as MediciNova, Eli Lilly and Company, AstraZeneca, Inventiva Pharma, Oasis Pharmaceuticals, LLC, Madrigal Pharmaceuticals, Inc., BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Hepion Pharmaceuticals, Inc., and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur

[email protected]

+14699457679

www.delveinsight.com 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/post-bariatric-hypoglycemia-market-to-register-stunning-growth-at-a-16-4-cagr-through-2036-owing-to-the-emergence-of-novel-drug-classes-such-as-glp-1-receptor-antagonists-sglt1-inhibitors-crh-inhibitors-and-sstr5-agonists–de-302819071.html

Disclaimer: The above press release comes to you under an arrangement with PR Newswire. UK Newshour takes no editorial responsibility for the same.